There is a good chance Sarepta Therapeutics Inc. (SRPT) will undergo another restructuring.

After finishing at $109.96 in the prior trading day, Sarepta Therapeutics Inc. (NASDAQ: SRPT) closed at $112.00, up 1.86%. In other words, the price has increased by $+2.04 from its previous closing price. On the day, 847502 shares were traded. SRPT stock price reached its highest trading level at $113.04 during the session, while it also had its lowest trading level at $110.49.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Ratios:

Our goal is to gain a better understanding of SRPT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.00 and its Current Ratio is at 4.40. In the meantime, Its Debt-to-Equity ratio is 3.58 whereas as Long-Term Debt/Eq ratio is at 3.58.

Upgrades & Downgrades

On January 05, 2022, Needham reiterated its Buy rating and also upped its target price recommendation from $157 to $150.

Oppenheimer Upgraded its Perform to Outperform on December 09, 2021, while the target price for the stock was maintained at $125.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 14 when Chambers Michael Andrew bought 57,100 shares for $104.43 per share. The transaction valued at 5,963,124 led to the insider holds 108,178 shares of the business.

Chambers Michael Andrew bought 46,170 shares of SRPT for $4,999,230 on Aug 19. The Director now owns 51,078 shares after completing the transaction at $108.28 per share. On Nov 24, another insider, Rodino-Klapac Louise, who serves as the Head of R&D, CSO of the company, bought 3,780 shares for $79.33 each. As a result, the insider paid 299,867 and bolstered with 65,678 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 11.02 while its Price-to-Book (P/B) ratio in mrq is 22.76.

Stock Price History:

Over the past 52 weeks, SRPT has reached a high of $120.23, while it has fallen to a 52-week low of $61.28. The 50-Day Moving Average of the stock is 110.46, while the 200-Day Moving Average is calculated to be 89.68.

Shares Statistics:

The stock has traded on average 1.05M shares per day over the past 3-months and 885.41k shares per day over the last 10 days, according to various share statistics. A total of 87.63M shares are outstanding, with a floating share count of 83.68M. Insiders hold about 0.20% of the company’s shares, while institutions hold 89.10% stake in the company. Shares short for SRPT as of Oct 13, 2022 were 7.24M with a Short Ratio of 8.04M, compared to 6.82M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 8.27% and a Short% of Float of 8.66%.

Earnings Estimates

Its stock is currently analyzed by 13 different market analysts. On average, analysts expect EPS of -$1.43 for the current quarter, with a high estimate of -$0.81 and a low estimate of -$2.05, while EPS last year was -$0.6. The consensus estimate for the next quarter is -$1.44, with high estimates of -$1.02 and low estimates of -$1.81.

Analysts are recommending an EPS of between -$5.71 and -$7.71 for the fiscal current year, implying an average EPS of -$6.71. EPS for the following year is -$4.59, with 15 analysts recommending between -$2.42 and -$8.43.

Revenue Estimates

16 analysts predict $234.52M in revenue for the current quarter. It ranges from a high estimate of $243.24M to a low estimate of $230.18M. As of the current estimate, Sarepta Therapeutics Inc.’s year-ago sales were $189.41M, an estimated increase of 23.80% from the year-ago figure. For the next quarter, 16 analysts are estimating revenue of $242.44M, an increase of 20.30% less than the figure of $23.80% in the same quarter last year. There is a high estimate of $256.02M for the next quarter, whereas the lowest estimate is $235.3M.

A total of 17 analysts have provided revenue estimates for SRPT’s current fiscal year. The highest revenue estimate was $943.58M, while the lowest revenue estimate was $910.49M, resulting in an average revenue estimate of $921.64M. In the same quarter a year ago, actual revenue was $701.89M, up 31.30% from the average estimate. Based on 17 analysts’ estimates, the company’s revenue will be $1.21B in the next fiscal year. The high estimate is $1.68B and the low estimate is $1.03B. The average revenue growth estimate for next year is up 31.10% from the average revenue estimate for this year.